TransCode Therapeutics (Nasdaq: RNAZ): Featured in RedChip Investor Overview — Phase 2a Update RedChip shared an overview of TransCode Therapeutics, a company developing an RNA-based approach for metastatic cancer. Management discussed the company's lead candidate, TTX-MC138, which has completed a Phase 1a trial and moved into a Phase 2a clinical trial in colorectal cancer. TransCode is working to bring a new therapeutic option to a disease category that remains the leading cause of cancer mortality. Watch the full overview: https://t.co/uCFlJWkY6c Transcode Therapeutics is a client of RedChip. Not investment advice. Do your own due diligence. $MRNA $ARWR $ALNY $IONS $SLN $SRPT
RedChipShare
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.